Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + linperlisib for relapsed/refractory follicular lymphoma
ChiCTR2300075964Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and linperlisib in follicular lymphoma (FL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: complete response. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tucidinostatlinperlisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2300075964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075964.